WO2011107960A1 - Compositions comprenant l'espèce lactobacillus mucosae pour une utilisation médicale - Google Patents
Compositions comprenant l'espèce lactobacillus mucosae pour une utilisation médicale Download PDFInfo
- Publication number
- WO2011107960A1 WO2011107960A1 PCT/IB2011/050913 IB2011050913W WO2011107960A1 WO 2011107960 A1 WO2011107960 A1 WO 2011107960A1 IB 2011050913 W IB2011050913 W IB 2011050913W WO 2011107960 A1 WO2011107960 A1 WO 2011107960A1
- Authority
- WO
- WIPO (PCT)
- Prior art keywords
- strains
- coli
- species
- probiotic
- strain
- Prior art date
Links
- 241000394636 Lactobacillus mucosae Species 0.000 title claims abstract description 103
- 239000000203 mixture Substances 0.000 title claims abstract description 38
- 241001465754 Metazoa Species 0.000 claims abstract description 79
- 239000006041 probiotic Substances 0.000 claims abstract description 52
- 235000018291 probiotics Nutrition 0.000 claims abstract description 52
- 230000000529 probiotic effect Effects 0.000 claims abstract description 48
- 235000013305 food Nutrition 0.000 claims abstract description 33
- 238000011282 treatment Methods 0.000 claims abstract description 33
- 241000588724 Escherichia coli Species 0.000 claims abstract description 27
- 230000002265 prevention Effects 0.000 claims abstract description 21
- 239000013589 supplement Substances 0.000 claims abstract description 16
- 241000282414 Homo sapiens Species 0.000 claims abstract description 8
- 230000001717 pathogenic effect Effects 0.000 claims description 55
- 230000001580 bacterial effect Effects 0.000 claims description 33
- 241000894007 species Species 0.000 claims description 20
- 108010063045 Lactoferrin Proteins 0.000 claims description 18
- 102000010445 Lactoferrin Human genes 0.000 claims description 18
- CSSYQJWUGATIHM-IKGCZBKSSA-N l-phenylalanyl-l-lysyl-l-cysteinyl-l-arginyl-l-arginyl-l-tryptophyl-l-glutaminyl-l-tryptophyl-l-arginyl-l-methionyl-l-lysyl-l-lysyl-l-leucylglycyl-l-alanyl-l-prolyl-l-seryl-l-isoleucyl-l-threonyl-l-cysteinyl-l-valyl-l-arginyl-l-arginyl-l-alanyl-l-phenylal Chemical compound C([C@H](N)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CS)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCC(N)=O)C(=O)N[C@@H](CC=1C2=CC=CC=C2NC=1)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCSC)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CCCCN)C(=O)N[C@@H](CC(C)C)C(=O)NCC(=O)N[C@@H](C)C(=O)N1CCC[C@H]1C(=O)N[C@@H](CO)C(=O)N[C@@H]([C@@H](C)CC)C(=O)N[C@@H]([C@@H](C)O)C(=O)N[C@@H](CS)C(=O)N[C@@H](C(C)C)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](CCCNC(N)=N)C(=O)N[C@@H](C)C(=O)N[C@@H](CC=1C=CC=CC=1)C(O)=O)C1=CC=CC=C1 CSSYQJWUGATIHM-IKGCZBKSSA-N 0.000 claims description 17
- 235000021242 lactoferrin Nutrition 0.000 claims description 17
- 229940078795 lactoferrin Drugs 0.000 claims description 17
- 238000000034 method Methods 0.000 claims description 17
- 239000000546 pharmaceutical excipient Substances 0.000 claims description 15
- 238000002360 preparation method Methods 0.000 claims description 15
- 235000021277 colostrum Nutrition 0.000 claims description 13
- 210000003022 colostrum Anatomy 0.000 claims description 13
- 239000012634 fragment Substances 0.000 claims description 12
- -1 semisolid Substances 0.000 claims description 10
- 239000007788 liquid Substances 0.000 claims description 9
- 238000002156 mixing Methods 0.000 claims description 9
- 230000003308 immunostimulating effect Effects 0.000 claims description 8
- 235000013336 milk Nutrition 0.000 claims description 8
- 239000008267 milk Substances 0.000 claims description 8
- 210000004080 milk Anatomy 0.000 claims description 8
- 239000000843 powder Substances 0.000 claims description 7
- 239000003963 antioxidant agent Substances 0.000 claims description 6
- 239000003755 preservative agent Substances 0.000 claims description 6
- 239000001828 Gelatine Substances 0.000 claims description 5
- 235000013351 cheese Nutrition 0.000 claims description 5
- 229920000159 gelatin Polymers 0.000 claims description 5
- 235000019322 gelatine Nutrition 0.000 claims description 5
- 230000008569 process Effects 0.000 claims description 5
- 239000000725 suspension Substances 0.000 claims description 5
- 239000002535 acidifier Substances 0.000 claims description 4
- 239000002775 capsule Substances 0.000 claims description 4
- 235000013365 dairy product Nutrition 0.000 claims description 4
- 239000000839 emulsion Substances 0.000 claims description 4
- 239000008187 granular material Substances 0.000 claims description 4
- 229960001438 immunostimulant agent Drugs 0.000 claims description 4
- 239000003022 immunostimulating agent Substances 0.000 claims description 4
- 239000006188 syrup Substances 0.000 claims description 4
- 235000020357 syrup Nutrition 0.000 claims description 4
- 235000020186 condensed milk Nutrition 0.000 claims description 3
- 235000008476 powdered milk Nutrition 0.000 claims description 3
- 235000013618 yogurt Nutrition 0.000 claims description 3
- 239000000969 carrier Substances 0.000 claims description 2
- 235000015203 fruit juice Nutrition 0.000 claims description 2
- 239000000499 gel Substances 0.000 claims description 2
- 239000007937 lozenge Substances 0.000 claims description 2
- 239000006072 paste Substances 0.000 claims description 2
- 239000003826 tablet Substances 0.000 claims description 2
- 229940095602 acidifiers Drugs 0.000 claims 2
- 238000004040 coloring Methods 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 239000004615 ingredient Substances 0.000 claims 1
- 208000005577 Gastroenteritis Diseases 0.000 abstract description 19
- 206010012735 Diarrhoea Diseases 0.000 description 47
- 244000309466 calf Species 0.000 description 44
- 241000894006 Bacteria Species 0.000 description 33
- 230000034994 death Effects 0.000 description 31
- 231100000517 death Toxicity 0.000 description 31
- 208000015181 infectious disease Diseases 0.000 description 30
- 241000282412 Homo Species 0.000 description 28
- 210000003608 fece Anatomy 0.000 description 18
- 230000003115 biocidal effect Effects 0.000 description 15
- 230000000968 intestinal effect Effects 0.000 description 15
- 241000283690 Bos taurus Species 0.000 description 14
- 238000002560 therapeutic procedure Methods 0.000 description 14
- 208000004232 Enteritis Diseases 0.000 description 13
- 235000015872 dietary supplement Nutrition 0.000 description 11
- 239000000047 product Substances 0.000 description 11
- 201000010099 disease Diseases 0.000 description 10
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 description 10
- CEAZRRDELHUEMR-URQXQFDESA-N Gentamicin Chemical compound O1[C@H](C(C)NC)CC[C@@H](N)[C@H]1O[C@H]1[C@H](O)[C@@H](O[C@@H]2[C@@H]([C@@H](NC)[C@@](C)(O)CO2)O)[C@H](N)C[C@@H]1N CEAZRRDELHUEMR-URQXQFDESA-N 0.000 description 9
- 229930182566 Gentamicin Natural products 0.000 description 9
- 229960002518 gentamicin Drugs 0.000 description 9
- 210000000936 intestine Anatomy 0.000 description 9
- 230000000694 effects Effects 0.000 description 8
- 230000002496 gastric effect Effects 0.000 description 8
- JVTAAEKCZFNVCJ-UHFFFAOYSA-N lactic acid Chemical compound CC(O)C(O)=O JVTAAEKCZFNVCJ-UHFFFAOYSA-N 0.000 description 8
- 238000012360 testing method Methods 0.000 description 8
- 239000003053 toxin Substances 0.000 description 8
- 231100000765 toxin Toxicity 0.000 description 8
- 108700012359 toxins Proteins 0.000 description 8
- 241000124008 Mammalia Species 0.000 description 7
- 239000003242 anti bacterial agent Substances 0.000 description 7
- 239000000796 flavoring agent Substances 0.000 description 7
- 101000798114 Homo sapiens Lactotransferrin Proteins 0.000 description 6
- 210000004027 cell Anatomy 0.000 description 6
- 238000011156 evaluation Methods 0.000 description 6
- 102000050459 human LTF Human genes 0.000 description 6
- 239000000126 substance Substances 0.000 description 6
- 241000271566 Aves Species 0.000 description 5
- 206010017964 Gastrointestinal infection Diseases 0.000 description 5
- 241000282887 Suidae Species 0.000 description 5
- 150000001413 amino acids Chemical class 0.000 description 5
- 235000013355 food flavoring agent Nutrition 0.000 description 5
- 210000001035 gastrointestinal tract Anatomy 0.000 description 5
- 239000008194 pharmaceutical composition Substances 0.000 description 5
- 230000003449 preventive effect Effects 0.000 description 5
- 235000020185 raw untreated milk Nutrition 0.000 description 5
- 230000004936 stimulating effect Effects 0.000 description 5
- XEEYBQQBJWHFJM-UHFFFAOYSA-N Iron Chemical compound [Fe] XEEYBQQBJWHFJM-UHFFFAOYSA-N 0.000 description 4
- 229940088710 antibiotic agent Drugs 0.000 description 4
- 238000009395 breeding Methods 0.000 description 4
- 230000001488 breeding effect Effects 0.000 description 4
- 239000003795 chemical substances by application Substances 0.000 description 4
- 238000011109 contamination Methods 0.000 description 4
- 230000006378 damage Effects 0.000 description 4
- 230000000369 enteropathogenic effect Effects 0.000 description 4
- 230000000688 enterotoxigenic effect Effects 0.000 description 4
- 230000028993 immune response Effects 0.000 description 4
- 235000014655 lactic acid Nutrition 0.000 description 4
- 239000004310 lactic acid Substances 0.000 description 4
- 239000000463 material Substances 0.000 description 4
- 244000052769 pathogen Species 0.000 description 4
- 231100000077 verocytotoxic Toxicity 0.000 description 4
- 230000002257 verocytotoxic effect Effects 0.000 description 4
- XLYOFNOQVPJJNP-UHFFFAOYSA-N water Substances O XLYOFNOQVPJJNP-UHFFFAOYSA-N 0.000 description 4
- 206010012741 Diarrhoea haemorrhagic Diseases 0.000 description 3
- 239000004150 EU approved colour Substances 0.000 description 3
- 241000194031 Enterococcus faecium Species 0.000 description 3
- 241000283073 Equus caballus Species 0.000 description 3
- 240000001046 Lactobacillus acidophilus Species 0.000 description 3
- 241000218588 Lactobacillus rhamnosus Species 0.000 description 3
- 241001494479 Pecora Species 0.000 description 3
- 241000288906 Primates Species 0.000 description 3
- 206010040047 Sepsis Diseases 0.000 description 3
- 239000002253 acid Substances 0.000 description 3
- 239000000654 additive Substances 0.000 description 3
- 230000001464 adherent effect Effects 0.000 description 3
- 239000003708 ampul Substances 0.000 description 3
- 230000009286 beneficial effect Effects 0.000 description 3
- 210000001842 enterocyte Anatomy 0.000 description 3
- 235000012041 food component Nutrition 0.000 description 3
- 239000005417 food ingredient Substances 0.000 description 3
- 238000004108 freeze drying Methods 0.000 description 3
- 230000008774 maternal effect Effects 0.000 description 3
- 235000013372 meat Nutrition 0.000 description 3
- 244000005700 microbiome Species 0.000 description 3
- 244000005706 microflora Species 0.000 description 3
- 210000000110 microvilli Anatomy 0.000 description 3
- 229940006093 opthalmologic coloring agent diagnostic Drugs 0.000 description 3
- 230000001575 pathological effect Effects 0.000 description 3
- 108090000623 proteins and genes Proteins 0.000 description 3
- 230000009467 reduction Effects 0.000 description 3
- 150000003839 salts Chemical class 0.000 description 3
- 239000000523 sample Substances 0.000 description 3
- 210000000813 small intestine Anatomy 0.000 description 3
- 230000009897 systematic effect Effects 0.000 description 3
- 230000001225 therapeutic effect Effects 0.000 description 3
- 208000019206 urinary tract infection Diseases 0.000 description 3
- 230000004584 weight gain Effects 0.000 description 3
- 235000019786 weight gain Nutrition 0.000 description 3
- 208000004998 Abdominal Pain Diseases 0.000 description 2
- 241001608472 Bifidobacterium longum Species 0.000 description 2
- 241000186015 Bifidobacterium longum subsp. infantis Species 0.000 description 2
- VTYYLEPIZMXCLO-UHFFFAOYSA-L Calcium carbonate Chemical compound [Ca+2].[O-]C([O-])=O VTYYLEPIZMXCLO-UHFFFAOYSA-L 0.000 description 2
- 241000282465 Canis Species 0.000 description 2
- 241000283707 Capra Species 0.000 description 2
- FBPFZTCFMRRESA-FSIIMWSLSA-N D-Glucitol Natural products OC[C@H](O)[C@H](O)[C@@H](O)[C@H](O)CO FBPFZTCFMRRESA-FSIIMWSLSA-N 0.000 description 2
- 208000005156 Dehydration Diseases 0.000 description 2
- 241000282324 Felis Species 0.000 description 2
- 241000186660 Lactobacillus Species 0.000 description 2
- 240000001929 Lactobacillus brevis Species 0.000 description 2
- 244000199866 Lactobacillus casei Species 0.000 description 2
- 241000186673 Lactobacillus delbrueckii Species 0.000 description 2
- 240000002605 Lactobacillus helveticus Species 0.000 description 2
- 240000006024 Lactobacillus plantarum Species 0.000 description 2
- 241000186604 Lactobacillus reuteri Species 0.000 description 2
- 201000009906 Meningitis Diseases 0.000 description 2
- 241000736262 Microbiota Species 0.000 description 2
- 206010035664 Pneumonia Diseases 0.000 description 2
- 241000283984 Rodentia Species 0.000 description 2
- 108010079723 Shiga Toxin Proteins 0.000 description 2
- 230000009471 action Effects 0.000 description 2
- 239000004480 active ingredient Substances 0.000 description 2
- 230000000996 additive effect Effects 0.000 description 2
- 238000004458 analytical method Methods 0.000 description 2
- 230000001775 anti-pathogenic effect Effects 0.000 description 2
- 235000015278 beef Nutrition 0.000 description 2
- 230000018044 dehydration Effects 0.000 description 2
- 238000006297 dehydration reaction Methods 0.000 description 2
- 231100000676 disease causative agent Toxicity 0.000 description 2
- 230000007613 environmental effect Effects 0.000 description 2
- 210000000981 epithelium Anatomy 0.000 description 2
- 238000002474 experimental method Methods 0.000 description 2
- 235000019634 flavors Nutrition 0.000 description 2
- 230000037406 food intake Effects 0.000 description 2
- 235000013350 formula milk Nutrition 0.000 description 2
- 238000007710 freezing Methods 0.000 description 2
- 230000008014 freezing Effects 0.000 description 2
- 230000036541 health Effects 0.000 description 2
- 230000003862 health status Effects 0.000 description 2
- 230000002949 hemolytic effect Effects 0.000 description 2
- 238000000338 in vitro Methods 0.000 description 2
- 230000002779 inactivation Effects 0.000 description 2
- 238000011534 incubation Methods 0.000 description 2
- 208000028774 intestinal disease Diseases 0.000 description 2
- 210000004347 intestinal mucosa Anatomy 0.000 description 2
- 229910052742 iron Inorganic materials 0.000 description 2
- HQKMJHAJHXVSDF-UHFFFAOYSA-L magnesium stearate Chemical compound [Mg+2].CCCCCCCCCCCCCCCCCC([O-])=O.CCCCCCCCCCCCCCCCCC([O-])=O HQKMJHAJHXVSDF-UHFFFAOYSA-L 0.000 description 2
- 238000004519 manufacturing process Methods 0.000 description 2
- 230000035772 mutation Effects 0.000 description 2
- 206010034674 peritonitis Diseases 0.000 description 2
- 235000018102 proteins Nutrition 0.000 description 2
- 102000004169 proteins and genes Human genes 0.000 description 2
- 238000009877 rendering Methods 0.000 description 2
- 239000002002 slurry Substances 0.000 description 2
- 239000000600 sorbitol Substances 0.000 description 2
- 238000010561 standard procedure Methods 0.000 description 2
- 210000001519 tissue Anatomy 0.000 description 2
- 230000001551 toxigenic effect Effects 0.000 description 2
- 238000002255 vaccination Methods 0.000 description 2
- 235000013343 vitamin Nutrition 0.000 description 2
- 239000011782 vitamin Substances 0.000 description 2
- 229940088594 vitamin Drugs 0.000 description 2
- 229930003231 vitamin Natural products 0.000 description 2
- HDTRYLNUVZCQOY-UHFFFAOYSA-N α-D-glucopyranosyl-α-D-glucopyranoside Natural products OC1C(O)C(O)C(CO)OC1OC1C(O)C(O)C(O)C(CO)O1 HDTRYLNUVZCQOY-UHFFFAOYSA-N 0.000 description 1
- 208000009304 Acute Kidney Injury Diseases 0.000 description 1
- GUBGYTABKSRVRQ-XLOQQCSPSA-N Alpha-Lactose Chemical compound O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@H]1O[C@@H]1[C@@H](CO)O[C@H](O)[C@H](O)[C@H]1O GUBGYTABKSRVRQ-XLOQQCSPSA-N 0.000 description 1
- 208000037157 Azotemia Diseases 0.000 description 1
- 208000035143 Bacterial infection Diseases 0.000 description 1
- 206010004053 Bacterial toxaemia Diseases 0.000 description 1
- 241000186000 Bifidobacterium Species 0.000 description 1
- 239000002028 Biomass Substances 0.000 description 1
- 102000009016 Cholera Toxin Human genes 0.000 description 1
- 108010049048 Cholera Toxin Proteins 0.000 description 1
- 208000002881 Colic Diseases 0.000 description 1
- 101100298295 Drosophila melanogaster flfl gene Proteins 0.000 description 1
- 206010059866 Drug resistance Diseases 0.000 description 1
- 101150039033 Eci2 gene Proteins 0.000 description 1
- 241000196324 Embryophyta Species 0.000 description 1
- 206010014896 Enterocolitis haemorrhagic Diseases 0.000 description 1
- 101710146739 Enterotoxin Proteins 0.000 description 1
- 206010053172 Fatal outcomes Diseases 0.000 description 1
- 208000032843 Hemorrhage Diseases 0.000 description 1
- 206010061218 Inflammation Diseases 0.000 description 1
- 235000013956 Lactobacillus acidophilus Nutrition 0.000 description 1
- 241000186840 Lactobacillus fermentum Species 0.000 description 1
- 241000509544 Lactobacillus gallinarum Species 0.000 description 1
- 241000194036 Lactococcus Species 0.000 description 1
- 239000006154 MacConkey agar Substances 0.000 description 1
- 240000002129 Malva sylvestris Species 0.000 description 1
- 235000006770 Malva sylvestris Nutrition 0.000 description 1
- 206010058780 Meningitis neonatal Diseases 0.000 description 1
- 206010037660 Pyrexia Diseases 0.000 description 1
- 208000033626 Renal failure acute Diseases 0.000 description 1
- 108020001027 Ribosomal DNA Proteins 0.000 description 1
- 241000282849 Ruminantia Species 0.000 description 1
- 241000194017 Streptococcus Species 0.000 description 1
- 241000194049 Streptococcus equinus Species 0.000 description 1
- 208000013222 Toxemia Diseases 0.000 description 1
- HDTRYLNUVZCQOY-WSWWMNSNSA-N Trehalose Natural products O[C@@H]1[C@@H](O)[C@@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-WSWWMNSNSA-N 0.000 description 1
- 108060008682 Tumor Necrosis Factor Proteins 0.000 description 1
- 102100040247 Tumor necrosis factor Human genes 0.000 description 1
- 238000010521 absorption reaction Methods 0.000 description 1
- 150000007513 acids Chemical class 0.000 description 1
- 239000012190 activator Substances 0.000 description 1
- 230000001154 acute effect Effects 0.000 description 1
- 201000011040 acute kidney failure Diseases 0.000 description 1
- 208000012998 acute renal failure Diseases 0.000 description 1
- 230000002776 aggregation Effects 0.000 description 1
- 238000004220 aggregation Methods 0.000 description 1
- HDTRYLNUVZCQOY-LIZSDCNHSA-N alpha,alpha-trehalose Chemical compound O[C@@H]1[C@@H](O)[C@H](O)[C@@H](CO)O[C@@H]1O[C@@H]1[C@H](O)[C@@H](O)[C@H](O)[C@@H](CO)O1 HDTRYLNUVZCQOY-LIZSDCNHSA-N 0.000 description 1
- 229960004977 anhydrous lactose Drugs 0.000 description 1
- 238000003975 animal breeding Methods 0.000 description 1
- 239000000427 antigen Substances 0.000 description 1
- 108091007433 antigens Proteins 0.000 description 1
- 102000036639 antigens Human genes 0.000 description 1
- 230000003078 antioxidant effect Effects 0.000 description 1
- 208000022362 bacterial infectious disease Diseases 0.000 description 1
- 230000027455 binding Effects 0.000 description 1
- 230000004071 biological effect Effects 0.000 description 1
- 239000012472 biological sample Substances 0.000 description 1
- 230000015572 biosynthetic process Effects 0.000 description 1
- 210000004369 blood Anatomy 0.000 description 1
- 239000008280 blood Substances 0.000 description 1
- 229910000019 calcium carbonate Inorganic materials 0.000 description 1
- 235000010216 calcium carbonate Nutrition 0.000 description 1
- 230000032823 cell division Effects 0.000 description 1
- 238000005119 centrifugation Methods 0.000 description 1
- 239000013522 chelant Substances 0.000 description 1
- 239000002577 cryoprotective agent Substances 0.000 description 1
- 238000012217 deletion Methods 0.000 description 1
- 230000037430 deletion Effects 0.000 description 1
- 238000011161 development Methods 0.000 description 1
- 230000001079 digestive effect Effects 0.000 description 1
- 208000019836 digestive system infectious disease Diseases 0.000 description 1
- 208000001848 dysentery Diseases 0.000 description 1
- 235000013399 edible fruits Nutrition 0.000 description 1
- 239000008151 electrolyte solution Substances 0.000 description 1
- 229940021013 electrolyte solution Drugs 0.000 description 1
- 239000000147 enterotoxin Substances 0.000 description 1
- 231100000655 enterotoxin Toxicity 0.000 description 1
- 238000000855 fermentation Methods 0.000 description 1
- 230000004151 fermentation Effects 0.000 description 1
- 235000013373 food additive Nutrition 0.000 description 1
- 239000002778 food additive Substances 0.000 description 1
- 239000005452 food preservative Substances 0.000 description 1
- 235000019249 food preservative Nutrition 0.000 description 1
- 239000008369 fruit flavor Substances 0.000 description 1
- 235000011389 fruit/vegetable juice Nutrition 0.000 description 1
- 239000001963 growth medium Substances 0.000 description 1
- 235000015220 hamburgers Nutrition 0.000 description 1
- 230000035876 healing Effects 0.000 description 1
- 238000010438 heat treatment Methods 0.000 description 1
- 208000007475 hemolytic anemia Diseases 0.000 description 1
- 244000038280 herbivores Species 0.000 description 1
- 235000012907 honey Nutrition 0.000 description 1
- 230000007366 host health Effects 0.000 description 1
- 230000002727 hyperosmolar Effects 0.000 description 1
- 230000002519 immonomodulatory effect Effects 0.000 description 1
- 238000003018 immunoassay Methods 0.000 description 1
- 238000010348 incorporation Methods 0.000 description 1
- 230000008595 infiltration Effects 0.000 description 1
- 238000001764 infiltration Methods 0.000 description 1
- 230000002757 inflammatory effect Effects 0.000 description 1
- 230000004054 inflammatory process Effects 0.000 description 1
- 229910052500 inorganic mineral Inorganic materials 0.000 description 1
- 229940039696 lactobacillus Drugs 0.000 description 1
- 229940039695 lactobacillus acidophilus Drugs 0.000 description 1
- 210000002429 large intestine Anatomy 0.000 description 1
- 231100000518 lethal Toxicity 0.000 description 1
- 230000001665 lethal effect Effects 0.000 description 1
- 210000000265 leukocyte Anatomy 0.000 description 1
- 244000144972 livestock Species 0.000 description 1
- 235000019359 magnesium stearate Nutrition 0.000 description 1
- 206010062198 microangiopathy Diseases 0.000 description 1
- 230000000813 microbial effect Effects 0.000 description 1
- 244000000010 microbial pathogen Species 0.000 description 1
- 239000011707 mineral Substances 0.000 description 1
- 210000003097 mucus Anatomy 0.000 description 1
- 230000003843 mucus production Effects 0.000 description 1
- 230000007935 neutral effect Effects 0.000 description 1
- 210000000056 organ Anatomy 0.000 description 1
- 230000008621 organismal health Effects 0.000 description 1
- 230000007918 pathogenicity Effects 0.000 description 1
- 230000007170 pathology Effects 0.000 description 1
- 239000008188 pellet Substances 0.000 description 1
- 230000002688 persistence Effects 0.000 description 1
- 230000002085 persistent effect Effects 0.000 description 1
- 229940124531 pharmaceutical excipient Drugs 0.000 description 1
- 230000035479 physiological effects, processes and functions Effects 0.000 description 1
- 239000013612 plasmid Substances 0.000 description 1
- 231100000572 poisoning Toxicity 0.000 description 1
- 230000000607 poisoning effect Effects 0.000 description 1
- 244000144977 poultry Species 0.000 description 1
- 230000035935 pregnancy Effects 0.000 description 1
- 102000004196 processed proteins & peptides Human genes 0.000 description 1
- 108090000765 processed proteins & peptides Proteins 0.000 description 1
- 230000001737 promoting effect Effects 0.000 description 1
- 230000000069 prophylactic effect Effects 0.000 description 1
- 230000005180 public health Effects 0.000 description 1
- 235000013580 sausages Nutrition 0.000 description 1
- 230000035945 sensitivity Effects 0.000 description 1
- 208000013223 septicemia Diseases 0.000 description 1
- RMAQACBXLXPBSY-UHFFFAOYSA-N silicic acid Chemical compound O[Si](O)(O)O RMAQACBXLXPBSY-UHFFFAOYSA-N 0.000 description 1
- 235000012239 silicon dioxide Nutrition 0.000 description 1
- 239000007787 solid Substances 0.000 description 1
- 230000000638 stimulation Effects 0.000 description 1
- 238000003860 storage Methods 0.000 description 1
- 208000024891 symptom Diseases 0.000 description 1
- 230000002195 synergetic effect Effects 0.000 description 1
- 239000000454 talc Substances 0.000 description 1
- 229910052623 talc Inorganic materials 0.000 description 1
- 235000012222 talc Nutrition 0.000 description 1
- 230000009967 tasteless effect Effects 0.000 description 1
- 206010043554 thrombocytopenia Diseases 0.000 description 1
- 231100000033 toxigenic Toxicity 0.000 description 1
- 229960005486 vaccine Drugs 0.000 description 1
- 238000010200 validation analysis Methods 0.000 description 1
- 235000013311 vegetables Nutrition 0.000 description 1
- 238000012795 verification Methods 0.000 description 1
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23L—FOODS, FOODSTUFFS, OR NON-ALCOHOLIC BEVERAGES, NOT COVERED BY SUBCLASSES A21D OR A23B-A23J; THEIR PREPARATION OR TREATMENT, e.g. COOKING, MODIFICATION OF NUTRITIVE QUALITIES, PHYSICAL TREATMENT; PRESERVATION OF FOODS OR FOODSTUFFS, IN GENERAL
- A23L33/00—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof
- A23L33/10—Modifying nutritive qualities of foods; Dietetic products; Preparation or treatment thereof using additives
- A23L33/135—Bacteria or derivatives thereof, e.g. probiotics
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P1/00—Drugs for disorders of the alimentary tract or the digestive system
- A61P1/12—Antidiarrhoeals
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N1/00—Microorganisms, e.g. protozoa; Compositions thereof; Processes of propagating, maintaining or preserving microorganisms or compositions thereof; Processes of preparing or isolating a composition containing a microorganism; Culture media therefor
- C12N1/20—Bacteria; Culture media therefor
- C12N1/205—Bacterial isolates
-
- A—HUMAN NECESSITIES
- A23—FOODS OR FOODSTUFFS; TREATMENT THEREOF, NOT COVERED BY OTHER CLASSES
- A23V—INDEXING SCHEME RELATING TO FOODS, FOODSTUFFS OR NON-ALCOHOLIC BEVERAGES AND LACTIC OR PROPIONIC ACID BACTERIA USED IN FOODSTUFFS OR FOOD PREPARATION
- A23V2002/00—Food compositions, function of food ingredients or processes for food or foodstuffs
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12R—INDEXING SCHEME ASSOCIATED WITH SUBCLASSES C12C - C12Q, RELATING TO MICROORGANISMS
- C12R2001/00—Microorganisms ; Processes using microorganisms
- C12R2001/01—Bacteria or Actinomycetales ; using bacteria or Actinomycetales
- C12R2001/225—Lactobacillus
Definitions
- the present description refers to the use of one or more strain of the species Lactobacillus mucosae in the treatment and/or prevention of gastroenteritis from £ coli in animals including humans and pharmaceutical or veterinary compositions, probiotics food, additives and food supplements containing the same.
- Escherichia coli is a commensal bacterium making up the microflora of the gastrointestinal track of many animals, including humans. However, there are many £ coli strains with high pathogenicity that are responsible of enteritis, toxemia and septicemia.
- £. coli infection is, in fact, described as one of the major causes of enteritis.
- £ coli strain 0157:H7 has been for the first time identified as a pathogenic agent in 1982 following an enteric epidemic in the United States, associated with the consumption of contaminated hamburgers, having even fatal implications.
- £ coli Although it represents a common intestine inhabitant and plays a key role in the digestive process, there are situations in which £ coli can cause diseases in humans and animals. Some £ coli strains are the causative agent of intestinal and extra intestinal diseases such as urinary tract infections, meningitis, peritonitis, septicaemia and pneumonia.
- £ coli strains are toxigenic, i.e. producing toxins that can cause diarrhoea.
- Dysentery from £ coli is a common food-borne poisoning, because is mainly contracted by contaminated food. The contamination can take place from poorly cooked infected meat, from unpasteurized milk and cheese products, and from other food contaminated with faeces.
- £ coli produces four types of toxins that are differentiated by their different sensitivity to heat treatment, in heat-labile and thermostable, and for the toxigenic action (shiga toxin and haemolytic toxin, HlyA).
- the heat-labile toxin is very similar in its structure and function to cholera toxin. It contains one 'A' subunit and five 'B' subunits in an olotoxin. The B subunits contribute to the adhesion and to the entry of the toxin into the host intestinal cells, whereas the A subunit stimulates the cells to release water causing diarrhoea.
- ETEC enterotoxigenic £ coli
- HUS haemolytic uremic syndrome
- Stx-2 is able to bind with higher affinity to Gb3 expressed by renal cells, causing their destruction.
- Stx toxins are also capable of stimulating the TNF-a ad interleuchina-6 production that while supporting the inflammatory situation, promote the exposure of Gb3.
- £ coli 0157:H7 in contrast to other serotypes, does not ferment sorbitol, this allows its identification in Mac Conkey agar containing sorbitol (evaluating the colonies that lack the fermentation activity).
- the bacterial culture analysis must be accompanied by the identification of toxins by commercial immunoassay.
- the 0124, 0143 and 0164 strains can cause bloody diarrhoea (are also white blood cells are present), abdominal cramps and fever.
- Enteroaggregant £. coli Pathogenic strains EAEC are involved in a persistent watery diarrhoea in travellers and infants in developing countries. These strains express both Bfp and AAF/1 , AAF/2 and AAF/3 (all encoded by a plasmid), that are adhesion factors promoting colonization of the small intestine, with stimulation of mucus production. This forms a bio film that is able to isolate and aggregate bacteria. The aggregation is followed by a reduction of the microvilli length, mononucleata infiltration and haemorrhage.
- VTEC verocytotoxic
- the clinical picture shows a lengthening of the microvilli of the enterocytes of the small intestine, with incorporation of bacteria in the enterocytes.
- £ coli infections in humans are mainly caused by the consumption of contaminated food (ground beef, unpasteurized milk, cured sausages, and cheese from raw milk).
- the highest contamination risk is relative to undercooked meat and unpasteurized milk.
- a significant risk is due to the contamination of acid foods, as pathogenic £ coli strains are known that have a marked acid tolerance which allows them to survive for long periods in the foods.
- £ coli contamination of foods is mainly due to the fact that livestock is the major reservoir of the £ coli bacterium.
- cattle such as calves are the most susceptible to infections caused by this bacterium.
- This infection in young individuals is characterized by high mortality due to enteritis during the first months of life, resulting in considerable economic losses for the farmer.
- the therapy against £ coli infections by consists in the administration of electrolyte solutions to restore the proper water and salt balance made preca riou s by dehyd ration with concom itant use of active anti biotics or, alternatively, in carrying out a prophylactic vaccination.
- US 5,965,128 patent describes a method for the treatment and prevention of £ coli 0157:1-17 infection in ruminants by using probiotics.
- the inventors isolate a number of bacterial strains from the gastrointestinal tract and faeces of adult bovines and report as a probiotic against £. coli 0157:1-17 infections at least one strain of £ coli selected from: £ coli 271 ATCC 20220, £ coli 786 ATCC 202018 and £ coli 797 ATCC 202019.
- Such strains, belonging to the same pathogenic species are, according to the inventors among those isolated, the only ones that are capable to significantly inhibit the growth of £ coli 0157:H7.
- the patent application US 2006/0134082 describes a specific probiotic for the treatment and prevention of £. coli infection in calves. It is recalled here that in the state of the are, the calves appear to be particularly susceptible to £. coli gastrointestinal infections.
- the inventors selected strains to be used, among those present in the faeces of adult cattle, and show the combination of strains of Streptococcus bovis and Lactobacillus gallinarum as the one effective for reducing the presence of £ coli bacteria in the gastrointestinal tract of calves.
- the patent application WO2009/15571 1 claims a probiotic for the treatment and/or prevention of enteritis caused by £ coli in mammals, consisting of bacteria selected from Lactobacillus, Streptococcus, Lactococcus, Bifidobacterium In particular among the lactobacilli the £ coli species L. acidophilus, L. fermentum, L. rhamnosus are shown to be effective in infections.
- the present invention relates to one or more strain belonging to the Lactobacillus mucosae species to be used in the treatment and/or prevention in animals including humans of pathogenic £. coli bacillosis , pharmaceutical and/or veterinary compositions comprising one or more strain of the Lactobacillus mucosae species for use in the treatment and/or prevention of gastroenteritis caused by pathogenic £ coli in animals including humans, methods of preparing such compositions, probiotics foods or food supplements comprising one or more strain of the Lactobacillus mucosae species and methods of preparation of such foods or food supplements.
- the invention relates to: - one or more strain of the Lactobacillus mucosae species for use in the treatment and/or prevention in animals including humans of pathogenic E. coli bacillosis ;
- composition comprising at least one strain belonging to the Lactobacillus mucosae s peci es a n d o n e or m ore pharmaceutically acceptable excipient for use in the treatment and/or prevention in animals including humans of pathogenic £ coli bacillosis;
- probiotic food or a probiotic food supplement comprising at least one strain belonging to the L. mucosae species and suitable food ingredients and/or preservatives and/or acidifying and/or antioxidants and/or colouring agents and/or substance stimulating the immune response and/or further probiotic bacteria and/or dietary supplements and/or excipients;
- any one of claims from 14 to 16 comprising the step of mixing at least one strain belonging to the Lactobacillus mucosae species with preservatives and/or acidifying agents and/or antioxidant agents and/or further probiotic bacterial strains and/or dietary supplements and/or excipients suitable and the storage thereof in frozen or freeze-dried form.
- Table 1 shows the efficacy results of L. mucosae CCCF 3706 in preventing infections from pathogenic £. coli in calves to which L. mucosae was administered within the first 30 min after birth, after mixing with colostrum that can be maternal or artificial colostrum, (e.g., whole colostrum by Sloten).
- Table 2 shows the efficacy results of L. mucosae CCCF 3706 in gastroenteritis caused by pathogenic £ coli in calves to which freeze-dried L. mucosae was mixed with the artificial milk and administered for 20 days at the indicated dose.
- Table 3 L. mucosae effect in gastroenteritis caused by pathogenic £ coli in calves treated with probiotic for 60 days.
- Table 3 shows the efficacy results of L. mucosae CCCF 3706 in gastroenteritis caused by pathogenic E. coli in calves to which freeze-dried L. mucosae was mixed with the artificial milk and administered for 60 days at the indicated dose.
- Lactobacillus mucosae spp. L. mucosae spp.
- species of Lactobacillus mucosae L. mucosae are intended all the strains belonging to the L. mucosae specie.
- adult animal animals that are in a developmental stage corresponding to the paediatric age for men, a cow, for example, is defined not adult if aged between 0 and about 8 months of age.
- Probiotic bacteria bacteria that positively influence the health of the host, improving his intestinal microbial balance.
- E. coli strains that are causative agents of intestinal and extra intestinal diseases such as urinary tract infections, meningitis, peritonitis, septicaemia and pneumonia.
- pathogenic £ coli Included in the definition of pathogenic £ coli are:
- EHEC Enterohemorrhagic £ coli
- VTEC Verocytotoxic £ coli
- probiotic food/feed or probiotic dietary supplement it is meant a food/feed product containing living micro-organisms capable of producing a beneficial effect to the person who ingests it.
- fragments or biologically active derivates of lactoferrin it is meant parts of the molecule or modified forms of the molecule (such as deletion, mutation, addition of amino acids) that maintain the biological activity of lactoferrin (e.g., immunomodulating, in particular immunostimulatory).
- the present invention reports for the first time the effectiveness of strains of the species Lactobacillus mucosae as active principles in the treatment and/or prevention of gastroenteritis caused by pathogenic £ coli such as, for example, enteropathogenic £ coli (EPEC); enterotoxigenic £ coli (ETEC); enterohaemorrhagic £. coli (EHEC); enteroaggregative £ coli (EAEC); diffusely adherent £ coli (DAEC); enteroinvasive £ coli (EIEC); avian pathogenic £ coli (APEC); verocytotoxic £ coli (VTEC).
- pathogenic £ coli such as, for example, enteropathogenic £ coli (EPEC); enterotoxigenic £ coli (ETEC); enterohaemorrhagic £. coli (EHEC); enteroaggregative £ coli (EAEC); diffusely adherent £ coli (DAEC); enteroinvasive £ coli (EIEC); avian pathogenic £ coli (APEC);
- the executors of the present invention have in fact highlighted how strains of the bacterial species Lactobacillus mucosae when administrated even alones experimentally to individuals, show the ability to effectively fight and prevent infection by pathogenic £ coli.
- Lactobacillus mucosae species was firstly isolated in the gastrointestinal tract of pigs (Roos S et al. Lactobacillus mucosae sp. nov., "A new species with in vitro mucus-binding activity isolated from pig intestine.” International Journal of Systematic and Evolutionary Microbiology 2000, 50: 251 -258) and only in recent years its presence has been described among the species constituting the micro flora of the gastrointestinal tract of calves (Busconi M, Reggi S, Fogher C. "Evaluation of biodiversity of lactic acid bacteria microbiota in the calf intestine tracts.” Antonie Van Leeuwenhoek. 2008, 94:145-155).
- the Lactobacillus mucosae species can be isolated from biological samples such as faeces, gastrointestinal tissue samples and any other suitable sample known by the skilled person, belonging to animal species for which the presence of said species in the gastrointestinal micro flora has been described, such as, e.g., calves or pigs. Alternatively, they may be isolated, where present, from samples obtained from other animals, including humans according to standard procedures as, for example, described in Busconi M, Reggi S, Fogher C. Antonie Van Leeuwenhoek. 2008. 94:145-155.
- the starting sample is represented by gastrointestinal tissue samples obtained from calves, the averagely skilled person can isolate and identify the L.
- mucosae species following what is described in Material and Methods section of the scientific article of Busconi et al (Busconi M, Reggi S, Fogher C. Evaluation of biodiversity of lactic acid bacteria microbiota in the calf intestine tracts. Antonie Van Leeuwenhoek. 2008. 94: 145-155).
- the biological identification of the isolated species in the L. mucosae species can be carried out by analysis of gene sequence homology using, for example, the 16S ribosomal gene.
- one or more strains of Lactobacillus mucosae spp. can be used in treatment and/or prevention of gastroenteritis caused by pathogenic £ coli in animals, including humans.
- the association of two strains according to the present invention may also result in a synergistic effect of the two, i.e., the sum of the antipathogenic £ coli activity of each individual strain, is inferior to the antipathogenic activity of the strains used together.
- the strains can be selected from any L. mucosae strain known or isolated from samples and characterized using techniques known in the literature such as, for example, the one described in the materials and methods chapter (pp 147-148) in Busconi M, Reggi S, Fogher C. Antonie Van Leeuwenhoek. 2008. 94 herein incorporated by reference, or they can be selected among the ones deposited on March, 1 st 2010 at DSMZ, according to the Budapest Treaty with deposit receipt dated March 2 2010, and identified by deposit numbers DSM 23409 and DSM 23408, depositor Italstarter Sri. with deposit receipt of DSMZ dated March 2 2010, Such strains are identified in the present description, respectively, as L. mucosae CCCF 3706 and CCCF 3464.
- the above indicated strains can be in combination with human or animal, native or recombinant, lactoferrin or biologically active fragments thereof or biologically active derivatives thereof.
- lactoferrin or biologically active fragments thereof or biologically active derivatives thereof.
- an association with lactoferrin, fragments or derivatives thereof from the species in which they will perform prevention or the treatment for bacillosis from pathogenic £ coli will be made.
- the association with natural or recombinant lactoferrin or with fragments thereof or biologically active derivatives thereof of human origin will be preferred; or the treatment, e.g., of cattle or calves the association with natural or recombinant lactoferrin or fragments thereof or biologically active derivatives thereof cattle origins will be preferred etc.
- the mammals are selected in the group of: cattle, pigs, equines, sheep, primates (humans), canines, felines, rodents and goats.
- cattle, pigs, equines, sheep, primates humans
- canines felines
- rodents and goats canines, felines, rodents and goats.
- not adults (for humans in the paediatric age) infections from pathogenic £ coli can cause severe enteritis.
- breeding animals as for example cattle, the mortality in young individuals, not adults (e.g.. calves) due to those gastroenteritis is really frequent.
- one or more strain of the L. mucosae species are more effective in restoring the gastrointestinal balance in individuals affected by pathogenic £ coli enteritis when compared to commonly known probiotic bacterial strains for said use, such as, by way of example Streptococcus faecium.
- L. mucosae strains can hence be used for the prevention and the therapy of the above reported diseases caused by £ coli in a particularly advantageous way in humans of paediatric age and in subjects having an analogous age among animals, in physically debilitated subjects, in patients undergoing special medical treatment rendering them more susceptible to pathogenic £. coli infections and in elderly subjects that are less resistant to the above mentioned bacterial infections.
- L. mucosae strains as herein described is of particular importance as they are those most exposed to damages, even lethal, by the pathogenic microorganism.
- Any strain or combinations of strains belonging to the Lactobacillus mucosae species can be used, in particular, in the treatment or in the prevention of pathogenic £ coli gastroenteritis in paediatric age for humans and for not adult subjects for the remaining animals.
- strains as explained above allows avoiding, for example in animal breeding, or in epidemics, the propagation of the infection from other affected subjects or from healthy carriers of the pathogenic £ coli strain.
- the possible strains belonging to the L. mucosae species can be one or more among those deposited (CCCF 3706 and CCCF 3464) on March the 1 st, 2010 at DSMZ, according to the Budapest Treaty, and identified by deposit numbers DSM 23409 and DSM 23408, depositor Italstarter Sri. with deposit receipt of DSMZ dated March 2 2010, Such strains are identified in this description as L. mucosae CCCF 3706 and CCCF 3464.
- one or more strain belonging to this group optionally in combination with other L. mucosae strains can be used.
- Th e strains are useful and effective in preventing and treating in general pathogenic E. coli infections , for example, they can be useful in the treatment of infections by pathogenic £ coli such as enteropathogenic £ coli (EPEC); enterotoxigenic £. coli (ETEC); enterohaemorrhagic £ coli (EHEC); enteroaggregative £ coli (EAEC); diffusely adherent E.
- pathogenic £ coli such as enteropathogenic £ coli (EPEC); enterotoxigenic £. coli (ETEC); enterohaemorrhagic £ coli (EHEC); enteroaggregative £ coli (EAEC); diffusely adherent E.
- DAEC verocytotoxic £ coli
- VTEC verocytotoxic £ coli
- EIEC enteroinvasive £ coli
- APEC avian pathogenic £ coli
- strains belonging to these groups of £ coli are, for example, £ coli 0157: H7; 01 :K1 : H7; 045:K1 :H7; O78: K80: H9; 06:K2:H1 ; 04:K54:H5; 018:K1 :H7; 02:K1 :H5; 02:K1 :H7, etc.
- one or more strain belonging to the L. mucosae species can also be in freeze-dried and/or frozen form. Freeze-drying and freezing are to be intended as means for the temporary inactivation of the bacteria, that do not prevent the restoration of cell division, and that can be carried out in any one of the ways known to the skilled person that are reported in detail in laboratory manuals.
- Object of the present invention are also pharmaceutical (including paediatric pharmaceutical compositions) or veterinary compositions comprising at least one strain belonging to the L. mucosae species for use in the treatment and/or prevention of gastroenteritis caused by pathogenic £ coli in animals including humans.
- Such compositions will comprise an amount of L. mucosae bacteria in the range from 100 to 100,000 x 10 6 UFC per each single dose.
- compositions include also paediatric pharmaceutical compositions and compositions suitable for administration to baby animals.
- one or more pharmaceutically acceptable excipients may be present in the compositions.
- Suitable excipients can be: culture medium, calcium carbonate, silicic acid, talc, magnesium stearate, anhydrous lactose, gelatine, trehalose.
- a suitable stimulating substance could be the protein lactoferrin or peptides derived thereof.
- Th e compositions may comprise, as active ingredients, solely bacterial strains belonging to the L. mucosae species or can further comprise one or more bacterial strains belonging to probiotic bacterial species, that is to say, strains belonging to probiotic bacterial species other than L. mucosae.
- these species may be Lactobacillus acidophilus, L. rhamnosus, L. delbrueckii, L. helveticus, L. plantarum, L. gassei, L. casei, L. reuteri, Enterococcus faecium, Bifidobascterium animalis, B. breve, B. infantis, B. longum, etc.
- the bacterial strains belonging to the L. mucosae species useful for the preparation of the pharmaceutical or veterinary compositions can be selected from any L. mucosae strain known or isolated by samples and characterized using techniques known in the literature such as, for example, the one described in the chapter material and methods (pp 147-148) in Busconi M, Reggi S, Fogher C. Antonie Van Leeuwenhoek. 2008. 94 herein incorporated by reference or selected by: the ones deposited (DSM 23409 and DSM 23408, depositor Italstarter Sri, respectively CCCF 3706 and CCCF 3464) on 1 st of March 201 0 at DSMZ, with deposit receipt of DSMZ dated March 2 2010, according to the Budapest Treaty.
- Th e bacteria according to the present description may be suspended, freeze-dried or frozen, provided they are not killed because their vitality is essential for the preventive or therapeutic effect here disclosed bound to the probiotic activity of such bacteria.
- compositions of the invention can be carried out by freeze-drying of bacterial cultures, by a dmixing freeze-dried cultures or by suspension of bacterial pellets or colonies with water or with further suitable excipients, preservatives, flavouring, colouring agents.
- the bacteria can also be supplied in frozen form, stored according to standard techniques.
- excipients can be commonly used excipient for bacterial therapeutic or preventive preparations , of veterinary or pharmaceutical grade.
- compositions according to the invention are for use in the treatment and/or prevention of gastroenteritis caused by E. coli in animals including humans.
- these animals are mammals such as for example: cattle, pigs, equines, sheep, primates, canines, felines, goats, rodents and farm mammals, for breeding, competition or as pets.
- these pharmaceutical compositions comprising one or more Lactobacillus mucosae strains are used, in gastroenteritis caused by E. coli in humans of paediatric age, and their correspondent veterinary compositions can be particularly suitable for use with non adu lt animals in a development stage corresponding to the paediatric age of humans (puppies, for example calves).
- compositions will be of considerable utility when administered to new born or in the first months of age.
- compositions herein described can be provided in the form of powder, freeze-dried, in tablets, capsules, liquid, thick liquid, semisolid, gel, suspension, emulsion, slurry, syrup, elixir, lozenge, hard or soft gelatine capsule, granulate.
- flavouring agents that rendering their administration to kids or puppies easier.
- flavouring agents are obviously to be selected form the ones commonly used according to the desired patient. I n the case of children there flavouring agents having fruit flavour, honey flavour or other flavours commonly used by the skilled person can be used. For veterinary compositions, flavouring agents which make the composition more palatable for the desired animal can be used. Obviously these flavouring agents can be different if the patient is an herbivore or a carnivorous as known in the state of the art.
- compositions do be administered to newborns or before weaning, can conveniently be tasteless and odourless so to be, administrated together with maternal milk or alone, when necessary or desirable, without being rejected by the patient.
- Object of the present description are also probiotic foods and supplements or probiotic food additives comprising at least one strain belonging to the L. mucosae species.
- a foodstuff containing microorganism capable of reaching the intestines, multiply and exert a beneficial effect on health of the organism.
- That food or supplement besides containing as probiotic microorganism at least one strain of L. mucosae, will contain suitable food ingredients and/or activators of the immune response and/or preservatives and/or acidifying and/or antioxidant and/or colouring agents and/or further probiotic bacteria strains and/or food supplements (mineral salts, vitamins or others) and/or excipients.
- the bacteria of the L. mucosae species present in the food or supplement can belong to one or more strain, selected from any L. mucosae strain known or isolated by samples and characterized following techniques known in literature, such as, for example the one described in the chapter materials and methods (pp 147-148) in Busconi M, eggi S, Fogher C. Antonie Van Leeuwenhoek. 2008. 94 herein incorporated by reference.
- the food and supplements can contain one or more strain (for example two) belonging to the L. mucosae species as sole probiotic strains.
- such foods or supplements can comprise also strains belonging to different probiotic species for example the species Lactobacillus acidophilus, L. rhamnosus, L. delbrueckii, L. helveticus, L. plantarum, L. gassei, L.casei, L. reuteri, Enterococcus faecium, Bifidobascterium animalis, B. breve, B. infantis, B. longum.
- the foodstuff, the supplement or the additive can conveniently be, as of example and not as a limitation, in the form of liquid, thickened liquid, semisolid, solid, freeze-dried, powder, granules, paste, emu lsion , suspension, slurry, croquettes, chewable bars, yoghurt, cheese, juice or fruit compote, drink or dairy- food or non dairy food, gelatine, syrup, elixir, natural colostrum, artificial colostrum, condensed milk, powdered milk, flavoured powder, infant milk formula.
- Probiotic foods of particular interest can be foods intended for paediatric patients such as, for example, natural colostrum, artificial colostrum, condensed milk, powdered milk, flavoured powder, infant milk formula and homogenized food.
- the foodstuff is probiotic foods for use with animals, for example, croquettes.
- the foods of the invention can be prepared according to any of the methods known by the skilled person mixing at least one of the bacterial strains of L. mucosae in fresh, freeze-dried or frozen from, with suitable food ingredients and optionally preservatives and/or acidifying and/or antioxidant agents.
- probiotic bacterial strains not belonging to the L. mucosae species and/or supplements such as for example, vitamins, food salts, amino acids, immunostimulants and/or suitable excipients.
- one or more substance stimulating the immune response or capable of chelating iron may be present in the compositions or in the probiotic foods comprising as unique active ingredients or probiotic strains one or more L. mucosae strains as indicated above (optionally in combination with one or more further probiotic strain indicated above).
- lactoferrin a known immunostimulant
- This lactoferrin can be human lactoferrin, recombinant human lactoferrin (in the art many ways of producing recombinant human lactoferrin are known such as, for example, in plant seeds), fragments or derivatives thereof that retain the biologic immunostimulating activity of lactoferrin.
- the fragments can be part of the immunostimulating protein, and the derivatives can be forms of the protein, in which one or more amino acids can be deleted, added or mutated, that retain the immunostimulating characteristics of the lactoferrin .
- Derivatives in which the mutations are neutral, in which one or more amino acid is replaced by amino acids with the same characteristics (for example basic, acids etc.) are preferred.
- the lactoferrin can be human or animal lactoferrin, even if not necessary, a species-specific use of the lactoferrin is preferred, hence human lactoferrin (or derivatives or fragments thereof as described above) for pharmaceutical compositions and an imal lactoferrin (or derivatives or fragments thereof as described above) for veterinary compositions.
- the veterinary compositions can comprise lactoferrin (or derivatives or fragments thereof as described above) of the species to which they are designed.
- the amount of bacteria to be inserted in the foodstuffs can be any amount considered suitable by the skilled person.
- foods and probiotic supplements can comprise from 100 to 100,000 x 10 6 CFU per gram. These can be grown directly in the foodstuff or added in any preparation stage of the foodstuff.
- L. mucosae The marked effect of L. mucosae, at very high doses, on the intestine physiology worth consideration.
- the skilled person can easily distinguish a diarrhoea due to a pathogenic from an alimentary diarrhoea due to high doses of L. mucosae that resolves in few days, without any antibiotic therapy and without consequences for the animal. It is the first time that a phenomenon of this kind is observed after the administration of a probiotic and this testifies the physiological relevance of this bacterial species (L. mucosae) in the intestinal balance of the animal.
- the quantity to be administered can be calibrated, for each animal species, to avoid episodes of physiological imbalance that however have no consequences on the animal, as they resolve spontaneously in a few days and are not evidenced with adequate dosages (100 x 10 6 ).
- CCCF 3706 deposit number DSM 23409 deposited at DSMZ
- Italstarter Sri according to the Budapest Treaty on th e 1 st of March 2010 with deposit receipt of DSMZ dated March 2 2010
- Formulated in a blended frozen product mixing the bacterial biomass harvested after centrifugation of the fermented in a suitable cryoprotectant. The preparation thus obtained in administrated within the first 30 minutes from birth to the calves. Different concentrations of L.
- mucosae where tested and the effectiveness of the treatment has been evaluated (i) in terms of reduced percent of diarrhoea episodes in early life period (1 st-10th day), (ii) as reduction of coliform bacterial load in the faeces of the treated animals, (iii) with assessment of the health status of the animal after 30 days from the treatment. As shown in table 1 it is possible to highlight that L.
- mucosae when administered in a dose comprised between 100 and 100,000 X 10 6 CFU) within 30 minutes from birth can (i) completely contrast the onset of diarrhoea phenomena due to colibacillosis, (ii) induce a significant decrease of the presence of coliform in faeces, (iii) determine a good state of health after 30 days from the treatment with higher weight gain than the one of non treated animals or of animals treated with antibiotics. For the control animals, for which diarrhoea and an high bacterial load were observed, it has been necessary take action with a antibiotic therapy (gentamicin) on the 10th day after birth to remove the infection.
- gentamicin antibiotic therapy
- composition has been formulated as frozen 8 ml single dose bacterial product of the strain of the L. mucosae stored at -20°C and administered, after defrost at 30°C, in the first minutes from birth mixing it with 50/100 ml of colostrum.
- Cells of L mucosae strain CCCF 3706 (number of deposit DSM 23409) deposited on 1 st of March 2010 at DSMZ, with DSMZ deposit receipt on March 2 2010 depositor Italstarter Sri according to the Budapest Treaty has been lyophilized and diluted, using suitable inert substances, at a CFU concentration desired for the administration at the dose of 1 0 g for each animal per day, after mixing in milk.
- suitable inert substances were suitable, at the dosage of 10 g day/animal, for the administration of several bacterial concentrations between 100 and 100,000 x 1 0 6 CFU.
- the administration to the calves has been continued for 20 days or 60 days starting from the first day after birth without preliminary administration of the colostrum containing L.
- L. mucosae in the frozen form As highlighted from the obtained results reported in table 2 and table 3 the administration of L. mucosae is effective at the different concentrations used against the pathogenic E. coli infections.
- concentrations of L. mucosae have been tested and the efficacy of the treatment has been evaluated (i) in terms of reduced percent of diarrhoea episodes in early life (1 st-10th day), (ii) as reduction of coliform bacteria in the faeces of the treated animals, (iii) with assessment of the health status of the animal after 30 days from the treatment. As shown in table 2 and 3 it is possible to highlight that L.
- mucosae when administered in a dose between 100 and 100,000 X 10 6 CFU) for 20 or 60 days after birth can (i) completely contrast the onset of diarrhoea phenomena due to colibacillosis, (ii) induce a significant decrease of the presence of coliform in faeces, (iii) determine a good state of health at 30 and 60 days from the treatment with higher weight gain than with respect to non treated animals or to animals treated with antibiotics. For the control animals, for which diarrhoea and high bacterial load were observed, it has been necessary take action with an antibiotic therapy (gentamicin) on the 10th day after birth to remove the infection. The evaluation of the effectiveness of L. mucosae in the treatment of pathogenic E.
- the L. mucosae strains used in the experiment reported above have been isolated from sample coming from different breeding farms.
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Engineering & Computer Science (AREA)
- General Health & Medical Sciences (AREA)
- Organic Chemistry (AREA)
- Medicinal Chemistry (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Animal Behavior & Ethology (AREA)
- Pharmacology & Pharmacy (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Microbiology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Mycology (AREA)
- Genetics & Genomics (AREA)
- Biotechnology (AREA)
- Nutrition Science (AREA)
- Molecular Biology (AREA)
- Polymers & Plastics (AREA)
- Epidemiology (AREA)
- Food Science & Technology (AREA)
- Tropical Medicine & Parasitology (AREA)
- Virology (AREA)
- Biomedical Technology (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Biochemistry (AREA)
- General Engineering & Computer Science (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Coloring Foods And Improving Nutritive Qualities (AREA)
Abstract
La présente invention porte sur l'utilisation d'une ou plusieurs souches appartenant à l'espèce Lactobacillus mucosae pour le traitement et/ou la prévention de gastroentérite provoquée par Escherichia coli chez des animaux, incluant l'humain, et des compositions pharmaceutiques ou vétérinaires, des aliments probiotiques et des compléments alimentaires comprenant celles-ci.
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
ITRM2010A000088 | 2010-03-03 | ||
ITRM2010A000088A IT1398875B1 (it) | 2010-03-03 | 2010-03-03 | Composizioni contenti l. mucosae per uso medico. |
Publications (1)
Publication Number | Publication Date |
---|---|
WO2011107960A1 true WO2011107960A1 (fr) | 2011-09-09 |
Family
ID=42734785
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
PCT/IB2011/050913 WO2011107960A1 (fr) | 2010-03-03 | 2011-03-03 | Compositions comprenant l'espèce lactobacillus mucosae pour une utilisation médicale |
Country Status (2)
Country | Link |
---|---|
IT (1) | IT1398875B1 (fr) |
WO (1) | WO2011107960A1 (fr) |
Cited By (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2552230A2 (fr) * | 2010-03-29 | 2013-02-06 | Technische Universität München | Aliment pour animaux destiné aux veaux visant à un conditionnement de la flore intestinale |
WO2013093561A1 (fr) | 2011-12-21 | 2013-06-27 | Compagnie Gervais Danone | Nouvelle souche de lactobacillus mucosae |
CN105505815A (zh) * | 2015-11-30 | 2016-04-20 | 南昌大学 | 一株抗衰老功能的粘膜乳杆菌 |
CN112877231A (zh) * | 2019-11-29 | 2021-06-01 | 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) | 具有抑菌和抗氧化活性的乳酸菌及其应用 |
Families Citing this family (1)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
AU2022294135A1 (en) * | 2021-06-18 | 2023-12-14 | Chr. Hansen A/S | Compositions for increasing resilience towards bacterial infections |
Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5965128A (en) | 1997-08-13 | 1999-10-12 | University Of Georgia Research Foundation Inc. | Control of enterohemorrhagic E. coli 0157:H7 in cattle by probiotic bacteria and specific strains of E. coli |
US20060134082A1 (en) | 2002-06-06 | 2006-06-22 | Baillon Marie-Louise A | Mammalian animal compositon |
US20080274162A1 (en) * | 2007-05-04 | 2008-11-06 | Jeffrey Nessa | Method, composition, and delivery mode for treatment of prostatitis and other urogenital infections using a probiotic rectal suppository |
WO2009155711A1 (fr) | 2008-06-27 | 2009-12-30 | University Of Guelph | Analyse des molécules d'interférence « signal » la-5 de lactobacillus acidophilus |
-
2010
- 2010-03-03 IT ITRM2010A000088A patent/IT1398875B1/it active
-
2011
- 2011-03-03 WO PCT/IB2011/050913 patent/WO2011107960A1/fr active Application Filing
Patent Citations (4)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US5965128A (en) | 1997-08-13 | 1999-10-12 | University Of Georgia Research Foundation Inc. | Control of enterohemorrhagic E. coli 0157:H7 in cattle by probiotic bacteria and specific strains of E. coli |
US20060134082A1 (en) | 2002-06-06 | 2006-06-22 | Baillon Marie-Louise A | Mammalian animal compositon |
US20080274162A1 (en) * | 2007-05-04 | 2008-11-06 | Jeffrey Nessa | Method, composition, and delivery mode for treatment of prostatitis and other urogenital infections using a probiotic rectal suppository |
WO2009155711A1 (fr) | 2008-06-27 | 2009-12-30 | University Of Guelph | Analyse des molécules d'interférence « signal » la-5 de lactobacillus acidophilus |
Non-Patent Citations (9)
Title |
---|
BUSCONI M, REGGI S, FOGHER C., ANTONIE VAN LEEUWENHOEK, vol. 94, 2008 |
BUSCONI M, REGGI S, FOGHER C., ANTONIE VAN LEEUWENHOEK, vol. 94, 2008, pages 145 - 155 |
BUSCONI M, REGGI S, FOGHER C.: "Evaluation of biodiversity of lactic acid bacteria microbiota in the calf intestine tracts", ANTONIE VAN LEEUWENHOEK, vol. 94, 2008, pages 145 - 155 |
DE ANGELIS M ET AL: "Selection of potential probiotic lactobacilli from pig feces to be used as additives in pelleted feeding", RESEARCH IN MICROBIOLOGY, ELSEVIER, AMSTERDAM, NL LNKD- DOI:10.1016/J.RESMIC.2006.05.003, vol. 157, no. 8, 1 October 2006 (2006-10-01), pages 792 - 801, XP025101104, ISSN: 0923-2508, [retrieved on 20061001] * |
INIGUEZ-PALOMARES C ET AL: "Evaluation of probiotic properties in Lactobacillus isolated from small intestine of piglets", REVISTA LATINOAMERICANA DE MICROBIOLOGIA 200807 MX, vol. 49, no. 3-4, July 2008 (2008-07-01), pages 46 - 54, XP002602069, ISSN: 0187-4640 * |
KLOSE V ET AL: "In vitro antagonistic activities of animal intestinal strains against swine-associated pathogens", VETERINARY MICROBIOLOGY 2010 ELSEVIER NLD LNKD- DOI:10.1016/J.VETMIC.2010.02.025, vol. 144, no. 3-4, 20 February 2010 (2010-02-20), pages 515 - 521, XP002602068, ISSN: 0378-1135 * |
ROOS S ET AL.: "A new species with in vitro mucus-binding activity isolated from pig intestine.", INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY, vol. 50, 2000, pages 251 - 258 |
ROOS S ET AL.: "Lactobacillus mucosae sp. nov., a new species with in vitro mucus-binding activity isolated from pig intestine", INTERNATIONAL JOURNAL OF SYSTEMATIC AND EVOLUTIONARY MICROBIOLOGY, vol. 50, 2000, pages 251 - 258 |
TZORTZIS G ET AL: "Modulation of anti-pathogenic activity in canine-derived Lactobacillus species by carbohydrate growth substrate", JOURNAL OF APPLIED MICROBIOLOGY 2004 GB LNKD- DOI:10.1111/J.1365-2672.2004.02172.X, vol. 96, no. 3, 2004, pages 552 - 559, XP002602070, ISSN: 1364-5072 * |
Cited By (9)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
EP2552230A2 (fr) * | 2010-03-29 | 2013-02-06 | Technische Universität München | Aliment pour animaux destiné aux veaux visant à un conditionnement de la flore intestinale |
WO2013093561A1 (fr) | 2011-12-21 | 2013-06-27 | Compagnie Gervais Danone | Nouvelle souche de lactobacillus mucosae |
CN104053767A (zh) * | 2011-12-21 | 2014-09-17 | 热尔韦·达诺尼公司 | 新的粘膜乳杆菌菌株 |
US9297049B2 (en) | 2011-12-21 | 2016-03-29 | Compagnie Gervais Danone | Strain of Lactobacillus mucosae |
RU2606770C2 (ru) * | 2011-12-21 | 2017-01-10 | Компани Жервэ Данон | Штамм lactobacillus mucosae для получения ферментированных пищевых продуктов |
CN105505815A (zh) * | 2015-11-30 | 2016-04-20 | 南昌大学 | 一株抗衰老功能的粘膜乳杆菌 |
CN105505815B (zh) * | 2015-11-30 | 2019-04-12 | 南昌大学 | 一株抗衰老功能的粘膜乳杆菌 |
CN112877231A (zh) * | 2019-11-29 | 2021-06-01 | 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) | 具有抑菌和抗氧化活性的乳酸菌及其应用 |
CN112877231B (zh) * | 2019-11-29 | 2023-06-23 | 中国农业科学院哈尔滨兽医研究所(中国动物卫生与流行病学中心哈尔滨分中心) | 具有抑菌和抗氧化活性的乳酸菌及其应用 |
Also Published As
Publication number | Publication date |
---|---|
ITRM20100088A1 (it) | 2011-09-04 |
IT1398875B1 (it) | 2013-03-21 |
Similar Documents
Publication | Publication Date | Title |
---|---|---|
Franz et al. | Enterococci as probiotics and their implications in food safety | |
García-Hernández et al. | Isolation, characterization and evaluation of probiotic lactic acid bacteria for potential use in animal production | |
Chambers et al. | The intestinal microbiota and its modulation for Salmonella control in chickens | |
Musa et al. | The potential benefits of probiotics in animal production and health | |
ASML A et al. | The beneficial role of probiotics in monogastric animal nutrition and health | |
Guerra et al. | Production of four potentially probiotic lactic acid bacteria and their evaluation as feed additives for weaned piglets | |
Corcionivoschi et al. | Probiotics-identification and ways of action | |
JP5710250B2 (ja) | 哺乳類乳汁微生物、それらを含有する組成物および乳腺炎の治療のためのそれらの使用 | |
US20150374765A1 (en) | Novel lactobacillus plantarum and composition comprising same | |
US9861665B2 (en) | Use of UVE bacteria for growth promotion in animals | |
Adjei-Fremah et al. | Probiotics and ruminant health | |
US20130071367A1 (en) | Animal feed for calves for conditioning the intestinal flora | |
EP3250217A1 (fr) | Composition destinée à être utilisée dans la prévention et/ou le traitement de la diarrhée chez les animaux | |
Mulder et al. | Intervention strategies: the use of probiotics and competitive exclusion microfloras against contamination with pathogens in pigs and poultry | |
EP1162987A1 (fr) | Composition pharmaceutique a usage medical et veterinaire utilisee pour regenerer la flore intestinale en cas de diarrhee ou de syndrome dyspeptique | |
CA3123125A1 (fr) | Souches , composition et procede d'utilisation | |
WO2011107960A1 (fr) | Compositions comprenant l'espèce lactobacillus mucosae pour une utilisation médicale | |
TW201902499A (zh) | 用於類鐸受體2活性化之組成物 | |
JP4903559B2 (ja) | 家畜・家禽類又は魚介類の感染防除剤 | |
US20140037605A1 (en) | Anticoccidial composition | |
Kassaify et al. | Effect of food protein supplements on Salmonella Enteritidis infection and prevention in laying hens | |
Malik et al. | Synbiotics: Safety and toxicity considerations | |
Frizzo et al. | The effect of supplementation with three lactic acid bacteria from bovine origin on growth performance and health status of young calves | |
Royan | The use of enterococci as probiotics in poultry | |
WO2017105267A1 (fr) | Nouvelle culture starter de probiotique pour usage humain et animal |
Legal Events
Date | Code | Title | Description |
---|---|---|---|
121 | Ep: the epo has been informed by wipo that ep was designated in this application |
Ref document number: 11717744 Country of ref document: EP Kind code of ref document: A1 |
|
NENP | Non-entry into the national phase |
Ref country code: DE |
|
122 | Ep: pct application non-entry in european phase |
Ref document number: 11717744 Country of ref document: EP Kind code of ref document: A1 |